These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [A phase II study of carboplatin in lung cancer. The Carboplatin Cooperative Study Group].
    Journal: Gan To Kagaku Ryoho; 1988 Sep; 15(9):2781-5. PubMed ID: 2843133.
    Abstract:
    A phase II study of carboplatin in ready-to-use solution (RTU) was conducted in patients with primary lung cancer at 9 institutes throughout Japan. Out of 44 patients entered in this trial, 38 were judged eligible by the extramural review committee. The overall response rate was 18.4% (7/38). The response rate for small cell lung carcinoma was 33.3% (6/18), against 5.0% (1/20) for non-small cell lung carcinoma. As for hematological toxicities, thrombocytopenia (less than 7 x 10(4)/mm3) and leukopenia (less than 3,000/mm3) were observed in 55.3% of cases, respectively. Nausea/vomiting was observed at an incidence of 60.5%. The clinical usefulness of carboplatin in RTU form was found to be comparable with that of carboplatin in lyophilized powder.
    [Abstract] [Full Text] [Related] [New Search]